Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.

ABSTRACT:

Importance

Combinations of chemotherapy with immunotherapy or bevacizumab in first-line treatments of extensive-stage small cell lung cancer (ES-SCLC) have been evaluated in various clinical trials. However, it remains unclear what the optimal combination regimen is.

Objective

To clarify which first-line combination regimen is associated with the best tumor response among patients with ES-SCLC.

Data sources

Electronic databases (PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science) were systematically searched to extract eligible literature from database inception to December 2019.

Study selection

Head-to-head randomized clinical trials on first-line treatments for patients with ES-SCLC were included with outcomes and toxic effects

SUBMITTER: Zhou T 

PROVIDER: S-EPMC7573680 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature